{"protocolSection": {"identificationModule": {"nctId": "NCT01043146", "orgStudyIdInfo": {"id": "COR-1-01"}, "secondaryIdInfos": [{"id": "EudraCT2008-007745-31", "type": "REGISTRY", "domain": "EudraCT"}], "organization": {"fullName": "Corimmun GmbH", "class": "INDUSTRY"}, "briefTitle": "Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-\u00df1 Receptor Antibody Cyclopeptide", "officialTitle": "A Single-Blind Placebo-Controlled Dose Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of Cor-1, An Anti-\u00df1 Receptor Antibody Cyclopeptide, in Five Different Strengths in Healthy Male Volunteers", "acronym": "COR-1-01"}, "statusModule": {"statusVerifiedDate": "2013-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-10"}, "primaryCompletionDateStruct": {"date": "2010-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-01-05", "studyFirstSubmitQcDate": "2010-01-05", "studyFirstPostDateStruct": {"date": "2010-01-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-10-26", "resultsFirstSubmitQcDate": "2013-03-05", "resultsFirstPostDateStruct": {"date": "2013-04-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-03-05", "lastUpdatePostDateStruct": {"date": "2013-04-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Corimmun GmbH", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Primary Trial objectives:\n\nTo evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160, 240 mg) in 50 healthy, male volunteers after single intravenous administration (8 subjects on verum per dose level, 10 subjects receiving placebo)\n\nSecondary objectives:\n\nTo evaluate safety and tolerability by using adverse events (AEs) and vital signs", "detailedDescription": "Primary Trial objective:\n\nTo evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160, 240 mg) in healthy, male volunteers after single intravenous administration\n\nSecondary objectives:\n\nTo evaluate safety and tolerability by using adverse events (AEs), vital signs including blood pressure/pulse rate (BP/PR), electrocardiographic examinations (12 lead ECG), evaluation of antibody titer and safety laboratory tests (biochemistry, hematology, coagulation, urinalysis)\n\nMethodology:\n\nMono-center, single-blind, dose escalating study with five dose levels (8 subjects on verum per dose level, 2 subjects receiving placebo) in a total of 50 volunteers."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["anti-beta1 adrenergic receptor", "autoantibody", "cyclic peptide", "heart failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 50, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "COR-1", "type": "ACTIVE_COMPARATOR", "description": "single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1", "interventionNames": ["Drug: COR-1"]}, {"label": "placebo", "type": "PLACEBO_COMPARATOR", "description": "intravenous 0.9 % NaCl", "interventionNames": ["Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "COR-1", "description": "single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1", "armGroupLabels": ["COR-1"], "otherNames": ["cyclic peptide"]}, {"type": "DRUG", "name": "placebo", "description": "intravenous 0.9 % NaCl", "armGroupLabels": ["placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Number of Participants Reporting Adverse Events (AEs)", "description": "To assess the safety and tolerability of COR-1.", "timeFrame": "45 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy, male Caucasians between 18 and 45 years of age, inclusive\n* Normotensive subjects (systolic BP \\<140 mmHg and diastolic BP \\<90 mmHg)\n* Body mass index (BMI) 19-27, minimal weight 60 kg\n* Negative results in HIV antibody, HBs antigen (HBsAg) and HCV tests, and negative result in anti-\u00df1-receptor-autoantibody screening\n* Signed Informed Consent Form\n* Normal or clinically irrelevant laboratory findings\n\nExclusion Criteria:\n\n* Autoimmune disorders\n* Kidney diseases\n* Liver diseases, liver function impairments", "healthyVolunteers": true, "sex": "MALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Mariola Lappo, MD", "affiliation": "ABX CRO", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "ABX-CRO", "city": "Goerlitz", "state": "Saxonia", "zip": "02826", "country": "Germany"}]}, "referencesModule": {"references": [{"pmid": "22968742", "type": "DERIVED", "citation": "Munch G, Boivin-Jahns V, Holthoff HP, Adler K, Lappo M, Truol S, Degen H, Steiger N, Lohse MJ, Jahns R, Ungerer M. Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail. 2012 Nov;14(11):1230-9. doi: 10.1093/eurjhf/hfs118. Epub 2012 Sep 11. Erratum In: Eur J Heart Fail. 2013 Apr;15(4):478. Dosage error in article text."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo", "description": "intravenous 0.9 % NaCl"}, {"id": "FG001", "title": "10 mg COR-1", "description": "single intravenous administration"}, {"id": "FG002", "title": "40 mg COR-1", "description": "single intravenous administration"}, {"id": "FG003", "title": "80 mg COR-1", "description": "single intravenous administration"}, {"id": "FG004", "title": "160 mg COR-1", "description": "single intravenous administration"}, {"id": "FG005", "title": "240 mg COR-1", "description": "single intravenous administration"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "8"}, {"groupId": "FG005", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "8"}, {"groupId": "FG005", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "intravenous 0.9 % NaCl"}, {"id": "BG001", "title": "10 mg COR-1", "description": "single intravenous administration"}, {"id": "BG002", "title": "40 mg COR-1", "description": "single intravenous administration"}, {"id": "BG003", "title": "80 mg COR-1", "description": "single intravenous administration"}, {"id": "BG004", "title": "160 mg COR-1", "description": "single intravenous administration"}, {"id": "BG005", "title": "240 mg COR-1", "description": "single intravenous administration"}, {"id": "BG006", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "8"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "50"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "8"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "50"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}]}]}]}, {"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "34.1", "spread": "8.61"}, {"groupId": "BG001", "value": "32.5", "spread": "7.09"}, {"groupId": "BG002", "value": "33.1", "spread": "8.94"}, {"groupId": "BG003", "value": "31.9", "spread": "7.77"}, {"groupId": "BG004", "value": "30.1", "spread": "8.66"}, {"groupId": "BG005", "value": "27.5", "spread": "8.35"}, {"groupId": "BG006", "value": "31.6", "spread": "8.15"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "8"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "50"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Number of Participants Reporting Adverse Events (AEs)", "description": "To assess the safety and tolerability of COR-1.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "45 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "intravenous 0.9 % NaCl"}, {"id": "OG001", "title": "10 mg COR-1", "description": "single intravenous administration"}, {"id": "OG002", "title": "40 mg COR-1", "description": "single intravenous administration"}, {"id": "OG003", "title": "80 mg COR-1", "description": "single intravenous administration"}, {"id": "OG004", "title": "160 mg COR-1", "description": "single intravenous administration"}, {"id": "OG005", "title": "240 mg COR-1", "description": "single intravenous administration"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "8"}, {"groupId": "OG004", "value": "8"}, {"groupId": "OG005", "value": "8"}]}], "classes": [{"title": "AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}]}]}, {"title": "SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "intravenous 0.9 % NaCl", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}, {"id": "EG001", "title": "10 mg COR-1", "description": "single intravenous administration", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 0, "otherNumAtRisk": 8}, {"id": "EG002", "title": "40 mg COR-1", "description": "single intravenous administration", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 3, "otherNumAtRisk": 8}, {"id": "EG003", "title": "80 mg COR-1", "description": "single intravenous administration", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 0, "otherNumAtRisk": 8}, {"id": "EG004", "title": "160 mg COR-1", "description": "single intravenous administration", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 0, "otherNumAtRisk": 8}, {"id": "EG005", "title": "240 mg COR-1", "description": "single intravenous administration", "seriousNumAffected": 1, "seriousNumAtRisk": 8, "otherNumAffected": 0, "otherNumAtRisk": 8}], "seriousEvents": [{"term": "not drug-related traumatic injury (achilles tendon) during sledging 8600 half-lives post drug admin.", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Injury by sheet metal used for tobogganing 18 days after drug administration. Hospitalisation for 3 days (2 nights). Plastic reconstruction of the Achilles tendon, antibiotic treatment and wound dressing. Ambulatory follow up 31 days later.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}], "otherEvents": [{"term": "feeling of cold at infusion site when drug was added to cold saline solution", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Caused by cold temperature of infusion solution. The event never reoccurred when solution was equilibrated to room temperature prior to injection.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 8}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The PI can discuss and publish trial results upon review of results communication by the sponsor. The sponsor can require changes to the communication."}, "pointOfContact": {"title": "Gary Peters, MD, Managing Director", "organization": "Corimmun, GmbH", "email": "gpeters7@its.jnj.com", "phone": "001-215 628-5257"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M15325", "name": "Sarcoidosis", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC15", "name": "Blood and Lymph Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4625", "name": "Autoantibodies", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}